Source: Photo by Glen Rushton, Unsplash

While Lilly counts its billions, China is rewriting the next-gen playbook.

This is not a post on GLP-1s, I promise!

Instead, this is all about a different kind of billion dollar bet from Lilly – and whether it’s likely to be outflanked by orthogonal approaches coming up on the inside rail.

Three companies, three distinct platforms, one question: what if the real innovation is happening elsewhere?

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers